2026-10-28 12:54:30 UTC#528973duplicateconfirmednews
Sandoz Group AG stock news
Sandoz Group AG stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire20 wire items
2026-10-28 09:49:00 UTC#527364duplicateconfirmednews
Sandoz shares remain under pressure following cautious 2026 sales growth outlook
2026-10-28 09:34:29 UTC#527488newreportednews
Sandoz warns EU proposal to remove amoxicillin from critical list threatens last European production facility
bloombergimportance 0.50trust 0.80Sandoz Group AG -0.50European Medicines Agency -0.30Amoxicillin -0.40+1 entities
2026-10-28 09:18:00 UTC#527236duplicateconfirmednews
Sandoz shares decline as company lowers 2026 sales growth guidance to 5-6% citing German market and supply constraints
2026-10-28 08:18:11 UTC#526941duplicateconfirmednews
Sandoz shares drop 5% as Q3 sales miss estimates and full-year growth outlook is lowered
2026-10-28 06:52:00 UTC#526522duplicateconfirmednews
Sandoz lowers 2026 sales growth outlook while raising core EBITDA margin forecast
2026-10-28 06:49:56 UTC#526504newconfirmednews
Sandoz lowers 2026 sales growth guidance to 5-6%, raises core EBITDA margin forecast to 23-23.5% after Q3 miss
2026-10-07 15:00:35 UTC#426610newconfirmednews
United Therapeutics wins appeal against Sandoz antitrust claims regarding Remodulin, MLex reports
2026-10-02 14:55:43 UTC#405973newreportednews
Sandoz to pay $400 million to settle US states' antitrust claims over generic drugs, MLex reports
2026-09-21 05:16:06 UTC#340359newconfirmednews
Sandoz Group gains FDA filing acceptance for generic tirzepatide and secures Canadian, Brazilian semaglutide nods
tradingviewimportance 0.50trust 0.70Sandoz Group AG +0.60Tirzepatide +0.50Semaglutide +0.50+2 entities
2026-09-18 12:24:24 UTC#333283duplicateconfirmednews
Sandoz secures Canadian approval for generic Ozempic and finalizes emicizumab biosimilar licensing deal
seeking alphaimportance 0.40trust 0.70Sandoz Group AG +0.50Novo Nordisk A/S -0.40Roche Holding AG -0.40+1 entities
2026-09-18 10:28:00 UTC#332667duplicateconfirmedpress release
mAbxience and Sandoz announce global licensing and development deal for emicizumab biosimilar
pr_newswireimportance 0.30trust 1.00mAbxience +0.40Sandoz Group AG +0.40Fresenius SE & Co. KGaA +0.20+2 entities
2026-09-18 10:28:00 UTC#332666duplicateconfirmednews
mAbxience and Sandoz finalize global licensing deal for emicizumab biosimilar
2026-09-18 05:21:11 UTC#331398newconfirmednews
Sandoz partners with Mabxience to develop emicizumab biosimilar for hemophilia market
2026-09-18 05:04:27 UTC#331342newconfirmednews
Sandoz receives Health Canada approval for generic semaglutide for type-2 diabetes
reutersimportance 0.60trust 0.90Sandoz Group AG +0.50Health Canada +0.30Semaglutide +0.40+1 entities
2026-09-14 15:44:14 UTC#308551newconfirmednews
Sandoz Group AG issues EUR 500 million bond with 4.835% coupon and 12-year maturity
2026-09-08 13:31:16 UTC#281150newreportednews
Sandoz CEO Saynor warns proposed U.S. tariffs on generic drugs could force price hikes or supply cuts
2026-09-08 09:25:30 UTC#279619duplicateconfirmednews
European markets decline on oil-driven inflation fears; Novartis shares remain under pressure
2026-09-08 07:17:18 UTC#279008duplicateconfirmednews
Sandoz reiterates Bio100 strategy: 100+ biosimilars by 2040, doubling sales and 30% EBITDA margin by 2035
2026-09-08 05:49:52 UTC#278643duplicateconfirmednews